Cocktail-Solvent Screening to Enhance Solubility, Increase Crystal Yield, and Induce Polymorphs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Cocktail-Solvent Screening to Enhance Solubility, Increase Crystal Yield, and Induce Polymorphs
The authors propose extending initial solvent screening for a single-solvent system to the cocktail solvent screening of binary and ternary solvent mixtures.


Pharmaceutical Technology
Volume 32, Issue 1

The crystal habits and length–breadth aspect ratios of sulfathiazole crystals produced by the 11 pure single solvents and 13 solvent mixtures of acetonitrile, n-propanol, and water by cooling are shown in Figures 10 and 11, respectively. In general, Form I possessed a needle-like morphology. Form II had a cuboid morphology. The morphology of Form III was a truncated hexagon and Form IV had a plate-like hexagonal morphology (9). If crystal habits alone are used as a visual guide, the major phases grown from the 11 pure single solvents were: Form I in MEK, acetone, benzyl alcohol, acetonitrile, and n-propanol; Form III in THF, DMF, ethanol, DMSO, and water; and Form IV in methanol. Clearly, the observation that Form I appeared with the same crystal habit from more than one solvent suggested that none of the available solvent–surface interactions could inhibit the addition of sulfathiazole molecules to the {010} face (9). A similar conclusion could be drawn for Form III and its fast-growing {110} face (9).


Figure 8
In the solvent mixture systems of acetonitrile:n-propanol:water, Form I was the major phase in the needle-like crystals grown in the solvent mixtures of (50:50:0), (45:45:10), (60:20:20), (0:50:50), and (50:0:50), judging by the crystal habits. Form III was the major phase in the truncated hexagonal crystals produced by mixtures of (80:10:10), (10:80:10), (33:33:33), (20:20:60), and (10:10:80). Form IV was the major phase in the plate-like hexagonal crystals generated in the solvent mixtures of (10:80:10), (10:45:45), (45:10:45), and (10:10:80). Unlike the crystal habits in the pure solvent systems, not all of the crystal habits in the solvent mixtures were well defined.


Figure 9
The authors speculated that the lack of definition was caused by the presence of various polymorphs in a crystal, as indicated by the DSC scans (see Figures 8 and 9), and not by the solvent–surface interactions. The average size of crystals grown in the solvent mixtures was larger than those grown in pure solvent systems. Because the DSC traces in Figures 8 and 9 were derived from the sulfathiazole crystals produced by spontaneous nucleation, if the high crystal yield given by a solvent mixture is desired, the polymorphic purity of sulfathiazole can be ensured by seeding (3).

Conclusion


Figure 10
Successful large-scale preparation of fine chemicals, and the manufacture of pharmaceuticals in particular, depends heavily on the solubility, crystal yield, and polymorphism of solid compounds and active pharmaceutical ingredients. The cocktail solvent screening method is a simple and inexpensive technique on a laboratory scale. It should be implemented together with the initial solvent screening approach to enhance the solubility of green solvents, increase crystal yield, and optimize the chances of finding the number of polymorphs by coupling with DSC.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here